NEXT Oncology

Running trials

• Not yet recruiting

  A Study of MC001 in Patients With Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) and Other Folate Receptor Alpha (FRα)-Expressing Solid Tumors

  NCT07909356· Phase 1· Source

• Recruiting

  Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.

  NCT07755436· Phase 1· Source

• Recruiting

  A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer

  NCT07321106· Phase 1· Source

• Recruiting

  A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

  NCT07109726· Phase 1/2· Source

• Recruiting

  Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

  NCT06922591· Phase 1/2· Source

• Recruiting

  STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas

  NCT06975293· Phase 1/2· Source

• Recruiting

  A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer

  NCT06609005· Phase 1/2· Source

• Recruiting

  A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

  NCT06440005· Phase 1· Source

• Recruiting

  Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC

  NCT06332755· Phase 1· Source

• Recruiting

  Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

  NCT06343402· Phase 1· Source

• Active, not recruiting

  Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors

  NCT06334432· Phase 1/2· Source

• Recruiting

  A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

  NCT06234423· Phase 1· Source

• Active, not recruiting

  A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

  NCT05787587· Phase 1· Source

• Active, not recruiting

  Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

  NCT05704985· Phase 1· Source

• Recruiting

  Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

  NCT05482893· Phase 1/2· Source

• Active, not recruiting

  A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors

  NCT05585320· Phase 1/2· Source

• Recruiting

  Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

  NCT05431270· Phase 1/2· Source

• Active, not recruiting

  A Study of NDI 1150-101 in Patients With Solid Tumors

  NCT05128487· Phase 1/2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer5 recruiting
• Pancreatic cancer5 recruiting
• Colorectal cancer3 recruiting
• Ovarian cancer3 recruiting
• Endometrial cancer2 recruiting
• Gastric and esophageal cancer2 recruiting
• Head and neck cancer2 recruiting
• Kidney cancer2 recruiting
• Liver and biliary tract cancer2 recruiting
• Prostate cancer2 recruiting
• Sarcoma2 recruiting
• Bladder cancer1 recruiting
• Cervical cancer1 recruiting
• Melanoma1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer

  NCT07408089· Phase 1· Source

• Terminated

  Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

  NCT06714617· Phase 1· Source

• Terminated

  Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types

  NCT06034860· Phase 1· Source

• Terminated

  Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications

  NCT05827614· Phase 1· Source

• Completed

  A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

  NCT05753722· Phase 1· Source

• Terminated

  SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation

  NCT05375084· Phase 1· Source

• Terminated

  A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors

  NCT05346484· Phase 1· Source